Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Pfizer
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03709680CT.gov Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03526250CT.gov Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | — | Completed | — | — | — |
NCT03155620CT.gov Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Medulloblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Palbociclib (this asset) | Pfizer | P2 | B · 57 |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Irinotecan | Pfizer | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P2 | B |
| Etoposide | Theodore S. Johnson | P2 | B |
| Indoximod | Theodore S. Johnson | P2 | B |
| Cyclophosphamide | Theodore S. Johnson | P2 | B |
| Tazemetostat | National Cancer Institute (NCI) | P2 | B |
| PI3K/MTOR INHIBITOR LY3023414 | National Cancer Institute (NCI) | P2 | B |
+42 more in the Medulloblastoma cohort
Other indications for Palbociclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 75 |
| Hormone Receptor-Positive Breast Cancer | — | P3 | BBB · 73 |
| Breast Cancer | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Palbociclib in Medulloblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/palbociclib-medulloblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →